Pheton - PTHL Enterprise Value-to-Revenue Multiple

Pheton Holdings Ltd (PTHL) - corporate logo

Pheton Holdings Ltd is strengthening its position through IT partnerships with Chinese oncology centers for precision brachytherapy. The EV/Sales multiple confirms the stability of the model, where the 39741.94 indicator determines the parameter status. The issuer is implementing closed-loop water systems for environmental sustainability, although the slow modernization of clinics within the narrow radiation software segment is temporarily limiting business margins.

PTHL (Pheton) Enterprise Value-to-Revenue Ratio history from 11/23/2025 to 01/16/2026

Financial and market metric breakdowns for Pheton Holdings (PTHL)

- cash and cash flow indicators:
Fundamental company valuation:Pheton PTHL
Finished products of ftzy.com.cn

Investors utilize this multiple to determine the real value of the business, excluding the impact of leverage and capital structure on the enterprise value-to-sales ratio. The calculation is based on the sum of market capitalization and net debt, which, combined with the stable server node utilization of Pheton Holdings Ltd. (PTHL), makes the enterprise value-to-revenue assessment an indicator of the infrastructure's resilience to external shocks.

Competitor analysis

HLN: Enterprise Value-to-Revenue Ratio|Kenvue Corp (KVUE) - Enterprise Value-to-Revenue Ratio|Verona Pharma PLC - Business Value to Revenue|Enterprise Value-to-Revenue Ratio Jyong Biotech Ltd|EV/Sales Multiple Ligand Corp|EV/Sales Multiple AMRX|Total Company Value-to-Revenue Ratio Perrigo Company plc|EV/Sales Multiple ALVO (Alvotech Biopharmaceuticals)|LQDA: Company Value to Revenue Ratio|Galapagos N.V. - EV/Sales Multiple|ANIP - EV/Sales Multiple|MNKD: EV/Sales Multiple|amphastar.com (AMPH) - EV/Sales Multiple|PCRX (Pacira Pharmaceuticals) - EV/Sales Multiple|Company Value to Revenue ARS Pharmaceuticals, Inc. (SPRY)|EV/Sales Multiple TBPH|AQST (Aquestive Therapeutics) - Business Value to Revenue|scPharmaceuticals, Inc. - Company Value to Revenue|Business Value to Revenue TECX|tonixpharma.com - EV/Sales Multiple|Business Value to Revenue SXTC (sxtchina.com)|Eupraxia Pharma (EPRX) - Enterprise Value-to-Revenue Ratio|Company Value to Revenue BioHarvest|Company Value to Revenue EXOZ|Company Value to Revenue Oramed Pharmaceuticals (ORMP)|Company Value to Revenue ENTX (Entera Bio Corp)|MindWalk Holdings Inc. - Company Value to Revenue Ratio|EV/Sales Multiple ABVC (ABVC BioPharma Inc)|CPIX - Company Value to Revenue|Quantum BioPharma Corp - EV/Sales Multiple|FGEN (fibrogen.com) - Company Value to Revenue Ratio|TELO (Telomir Pharmaceuticals) - Company Value to Revenue|Rani Therapeutics Holdings - Business Value to Revenue|Company Value to Revenue SNYR|Enterprise Value-to-Revenue Multiple rallybio.com RLYB|EV/Sales Multiple LEXX|PULM (Pulmatrix, Inc.) - Business Value to Revenue|EV/Sales Multiple APM (Aptorum Group Ltd)|LYRA - Company Value to Revenue|Impact BioMedical Inc - EV/Sales Multiple|Enterprise Value to Sales Volume TNFA|YCBD (cbdmd.com) - Company Value to Revenue|painreform.com - Business Value to Revenue|Company Value to Revenue CYTO|Enterprise Value-to-Revenue Ratio LIPO|Enterprise Value-to-Revenue Ratio optinose.com (OPTN)|PIRS (Pieris Pharma) - Business Value to Revenue|Enterprise Value-to-Revenue Ratio Procaps Group S.A. PROC|Total Company Value-to-Revenue Ratio petrospharma.com (PTPI)|QLI - Enterprise Value-to-Revenue Ratio|Business Value to Revenue SLRN (ACELYRIN)|TFF Pharmaceuticals, Inc (TFFP) - Enterprise Value-to-Revenue Ratio